(Total Views: 440)
Posted On: 09/08/2019 7:37:00 AM
Post# of 154090
Yeah, sorry, I meant the rumor was confirmed through the RP lawsuit. Not that RP initiated the conversation.
GSK and Pfizer have launched ViiV Healthcare, a specialist company delivering advances in treatment and care for people with HIV
With Pfizer and GSK partnering, wouldn’t either ViiV or GSK majority owner, lead the HIV discussion? Back then 85% GSK, 15% Pfizer, but now I believe a Japanese company has joined in.
http://www.pmlive.com/pharma_news/gsk_and_pfi...hiv_192341
ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer to deliver advances in treatment and care for people living with HIV, launched today.
Dr Dominique Limet, CEO of ViiV Healthcare, outlined the company's priorities: to stay relentless in the pursuit of new HIV medicines; to better understand the needs of people living with HIV; and to improve access to current medicines regardless of income or geography.
ViiV Healthcare has 10 medicines currently available including therapies such as Epzicom/Kivexa (abacavir sulfate and lamivudine) and Selzentry/Celsentri (maraviroc). Revenues from these available treatments, which generated sales of approximately £1.6bn in 2008, will provide the company with financial stability and support sustained investment in its pipeline and programmes.
GSK and Pfizer have launched ViiV Healthcare, a specialist company delivering advances in treatment and care for people with HIV
With Pfizer and GSK partnering, wouldn’t either ViiV or GSK majority owner, lead the HIV discussion? Back then 85% GSK, 15% Pfizer, but now I believe a Japanese company has joined in.
http://www.pmlive.com/pharma_news/gsk_and_pfi...hiv_192341
ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer to deliver advances in treatment and care for people living with HIV, launched today.
Dr Dominique Limet, CEO of ViiV Healthcare, outlined the company's priorities: to stay relentless in the pursuit of new HIV medicines; to better understand the needs of people living with HIV; and to improve access to current medicines regardless of income or geography.
ViiV Healthcare has 10 medicines currently available including therapies such as Epzicom/Kivexa (abacavir sulfate and lamivudine) and Selzentry/Celsentri (maraviroc). Revenues from these available treatments, which generated sales of approximately £1.6bn in 2008, will provide the company with financial stability and support sustained investment in its pipeline and programmes.
(0)
(0)
